Sovremennyy podkhod k vyboru lecheniya bol'nykh khronicheskoy obstruktivnoy bolezn'yu legkikh
- Autores: Ovcharenko S.I1
-
Afiliações:
- Edição: Nº 15 (2013)
- Páginas: 64-67
- Seção: Articles
- URL: https://journals.eco-vector.com/2073-4034/article/view/282376
- ID: 282376
Citar
Texto integral
Acesso aberto
Acesso está concedido
Acesso é pago ou somente para assinantes
Resumo
The article discusses the basic position of the last revision of the Global Initiative for Chronic Obstructive Pulmonary Disease (COPD) -GOLD-2011. GOLD-2011 revision offers a new classification of COPD with the identification of the four categories of patients (A, B, C, and D) depending on the severity of the clinical symptom, frequency and severity of exacerbations of bronchial obstruction. The new revision of the GOLD divides all medical drugs into first- and second-line therapy. Therapy is determined by clinical course of the disease, that is, belonging to a particular category - A, B, C or D. Approaches to the choice of treatment of COPD depending on the category of the patient are presented. In general, pharmacotherapy should be aimed at reducing the symptoms of COPD, reducing the frequency and severity of exacerbations, improving exercise tolerance and general state of patent.
Texto integral
Bibliografia
- Global Initiative for Chronic Obstructive Lung Diseases. Global Strategy for the Diagnosis, Management and Prevention of Chronic Obstructive Pulmonary Disease (Revised 2006). Глобальная стратегия диагностики, лечения и профилактики хронической обструктивной болезни легких. Пересмотр 2006 г. / Под ред. А.Г. Чучалина. М., 2006. 96 с.
- Bestall JC, Paul EA, Garrod R, et al. Usefulness of the Medical Research Council (MRC) dyspnoea scale as a measure of disability in patients with chronic obstructive pulmonary disease. Thorax 1999;54:581-86.
- Jones PW, Harding G, Berry P, et al. Development and first validation of the COPD Assessment Test. Eur Respir J 2009;34:648-54.
- Agusti A, Calverley PM, Celli B, et al. Characterisation of COPD heterogenity in the ECLIPSE cohort. Respir Res 2010;11:122.
- Global Initiative for Chronic Obstructive Lung Diseases. Global Strategy for the Diagnosis, Management and Prevention of Chronic Obstructive Pulmonary Disease (Revised 2011). Глобальная стратегия диагностики, лечения и профилактики хронической обструктивной болезни легких. Пересмотр 2011 г. Перевод с английского/ Под ред. А.С. Белевского. М., 2012. 80 с.
- Jones PW. Health status and the spiral of decline. COPD 2009;6:59-63.
- Dodd JW, Hogg L, Nolan J, et al. The COPD assessment test (CAT): response to pulmonary rehabilitation. A multicenter, prospective study. Thorax 2011;66:425-29.
- Hurst JR, Vestbo J, Anzueto A, et al. Susceptibillity to exacerbation in chronic obstructive pulmonary disease. N Engl J Med 2010;363:1128-38.
- Decramer M, Celli B, Kesten S, et al. Effect of tiotropium on outcomes in patients with moderate chronic obstructive pulmonary disease (UPLIFT): a prespecified subgroup analysis of a randomized controlled trial. Lancet 2009;374:1171-78.
- Donohue JF, Fogarty C, Lotvall J, et al. Once-daily bronchodilatators for chronic obstructive pulmonary disease: indacaterol versus tiotropium. Am J Respir Crit Care Med 2010;182:155-62.
- Чучалин А.Г., Овчаренко С.И., Авдеев С.Н., Айсанов З.Р., Белевский А.С. Место препарата Онбрез Бризхалер (индакатерол) в терапии хронической обструктивной болезни легких// Пульмонология 2011. № 6. С. 124-33.
Arquivos suplementares
